Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
6.93
-0.31 (-4.28%)
At close: Feb 11, 2026, 4:00 PM EST
6.93
0.00 (0.00%)
After-hours: Feb 11, 2026, 4:10 PM EST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
3.54
Revenue / Employee
$1,570,273
Employees
423
Market Cap
2.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
| Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 630.60M |
| Galapagos NV | 336.64M |
| Adaptive Biotechnologies | 276.98M |
| Wave Life Sciences | 109.23M |
| Beam Therapeutics | 55.70M |
| Ascentage Pharma Group International | 54.52M |
| Mesoblast | 17.20M |
| Immunome | 9.68M |
TLX News
- 21 days ago - Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure - Benzinga
- 4 weeks ago - Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals - Newsfile Corp
- 7 weeks ago - TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain - GlobeNewsWire
- 7 weeks ago - TLX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals - Newsfile Corp
- 7 weeks ago - Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions - GlobeNewsWire
- 7 weeks ago - TLX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals - GlobeNewsWire